Related Experiment Video
Updated: Jun 16, 2025
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Coronary Sinus Reducer Therapy for Refractory Angina and its Role in Modern Interventional Practice: A Contemporary
Kevin Cheng1,2, Jonathan M Hill2, Ranil de Silva1,2
1National Heart and Lung Institute, Imperial College London London, UK.
Insights
Coronary sinus reducer (CSR) implantation offers a new treatment for refractory angina, a growing cardiovascular challenge. This review examines CSR
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Medical Device Technology
Background:
- Refractory angina is a significant global health issue with limited treatment options.
- Increasing survival rates for coronary artery disease exacerbate this challenge.
- Residual symptoms post-revascularization create an unmet clinical need.
Purpose of the Study:
- To review the unmet needs in refractory angina management.
- To discuss the development and evidence for coronary sinus reducer (CSR) implantation.
- To explore the current role and future research directions for CSR.
Main Methods:
- Literature review of preclinical and clinical studies on CSR.
- Analysis of the device's development and implantation techniques.
- Discussion of current interventional cardiology practices.
Main Results:
- CSR implantation is an emerging therapeutic option for refractory angina.
- Preclinical and clinical data support the efficacy and safety of CSR.
- Evidence highlights CSR's potential role in managing complex cardiovascular conditions.
Conclusions:
- CSR implantation addresses a critical unmet need in refractory angina.
- Further research is needed to define the optimal role of CSR in clinical practice.
- CSR represents a promising advancement in interventional cardiology for angina management.
Abstract:
Coronary sinus reducer (CSR) implantation is an emerging treatment option for patients with refractory angina. This condition represents a major global cardiovascular healthcare challenge, with patients experiencing chronic anginal symptoms that significantly impair their quality of life and for whom few effective treatments exist. The clinical burden of refractory angina is only set to grow because of improved survival from coronary artery disease, increased life expectancy and the presence of residual angina after percutaneous or surgical coronary revascularisation. Therefore, new, effective, evidence-based therapies are urgently needed. In this review, we highlight the unmet clinical needs of patients with refractory angina, discuss the development of the CSR device and review the preclinical and clinical evidence base underlying CSR implantation. In addition, we discuss the current role of CSR implantation in contemporary interventional practice, highlighting knowledge gaps and discussing areas of on-going research.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:21Coronary Circulation
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...